60 Degrees Pharmaceuticals (SXTP) Income from Non-Controlling Interests (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Income from Non-Controlling Interests of -$941.0 for Q1 2026, down 25.13% year-over-year from -$1256.9 in Q1 2025, and down 88.58% quarter-over-quarter from -$499.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Income from Non-Controlling Interests for 5 consecutive years, with -$941.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests fell 25.13% year-over-year to -$941.0; the TTM figure through Mar 2026 stood at -$3356.0 (up 50.81% YoY), while the FY2025 annual figure was -$3167.0, up 62.99% from the prior year.
- Income from Non-Controlling Interests slipped to -$941.0 in Q1 2026 per SXTP's latest filing, from -$499.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $5390.0 in Q4 2022 and bottomed at -$33933.0 in Q4 2023.
- Historically, Income from Non-Controlling Interests has averaged -$3853.8 across 5 years, with a median of -$1337.5 in 2024.
- Annual changes were most pronounced in 2023 — Income from Non-Controlling Interests slumped 729.55% — and 2024, when it jumped 92.62%.
- 60 Degrees Pharmaceuticals' Income from Non-Controlling Interests stood at $5390.0 in 2022, then plunged by 729.55% to -$33933.0 in 2023, then jumped by 88.55% to -$3887.0 in 2024, then surged by 87.16% to -$499.0 in 2025, then slumped by 88.58% to -$941.0 in 2026.
- Business Quant data shows SXTP's Income from Non-Controlling Interests at -$941.0 in Q1 2026, -$499.0 in Q4 2025, and -$712.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -1,060.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -941.00 |
| Dec 31, 2025 | -499.00 |
| Sep 30, 2025 | -712.00 |
| Jun 30, 2025 | -1,204.00 |
| Mar 31, 2025 | -752.00 |
| Dec 31, 2024 | -3,887.00 |
| Sep 30, 2024 | -713.00 |
| Jun 30, 2024 | -1,471.00 |
| Mar 31, 2024 | -2,485.00 |
| Dec 31, 2023 | -33,933.00 |
| Sep 30, 2023 | -9,656.00 |
| Jun 30, 2023 | -7,036.00 |
| Mar 31, 2023 | 2,527.00 |
| Dec 31, 2022 | 5,390.00 |
| Sep 30, 2022 | -3,172.00 |
| Jun 30, 2022 | -3,117.00 |